Discover 783 paid clinical trials in Elk Grove, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 783
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
for
Advanced Extrapulmonary Neuroendocrine Carcinoma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05058651
Phase 2, Phase 3, Recruiting
Family Communications After Genetic Testing
for
Colon Adenocarcinoma, Colorectal Adenocarcinoma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07143487
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
for
Locally Advanced Pancreatic Adenocarcinoma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Davis CA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06998940
Phase 3, Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Elk Grove CA, Sacramento CA, Carmichael CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06876714
Phase 3, Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
for
Prostate Cancer (Adenocarcinoma)
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: Canadian Cancer Trials Group
Sex: Male
Age: 18+
Code: NCT06592924
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
for
Advanced Malignant Solid Neoplasm,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0+
Code: NCT05564377
Phase 2, Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT04566328
Phase 3, Recruiting
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
for
Biochemically Recurrent Prostate Carcinoma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: Male
Age: 18+
Code: NCT04423211
Phase 3, Recruiting
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
for
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT05806515
Phase 2, Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
for
Ovarian Carcinoma
Location: Elk Grove CA, Sacramento CA, Carmichael CA,
Sponsor: NRG Oncology
Sex: Female
Age: 35 - 50
Code: NCT04251052
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
for
Intracranial Meningioma, Recurrent Meningioma,
Location: Elk Grove CA, Sacramento CA, Carmichael CA, Woodland CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT02523014
Phase 2, Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab